Biogen Inc logo

BIIB - Biogen Inc Share Price

$286.66 0.5  0.2%

Last Trade - 3:35pm

Sector
Healthcare
Size
Large Cap
Market Cap £40.36bn
Enterprise Value £41.52bn
Revenue £10.88bn
Position in Universe 202nd / 6416
Bullish
Bearish
Unlock BIIB Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BIIB Revenue Unlock BIIB Revenue

Net Income

BIIB Net Income Unlock BIIB Revenue

Normalised EPS

BIIB Normalised EPS Unlock BIIB Revenue

PE Ratio Range

BIIB PE Ratio Range Unlock BIIB Revenue

Dividend Yield Range

BIIB Dividend Yield Range Unlock BIIB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIIB EPS Forecasts Unlock BIIB Revenue
Profile Summary

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated April 1, 1997
Public Since September 17, 1991
No. of Shareholders: 600
No. of Employees: 7,800
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Global 100, Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 184,447,218
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address 225 Binney St, CAMBRIDGE, 02142-1031, United States
Web https://www.biogen.com/
Phone +1 781 4642000
Contact ()
Auditors PricewaterhouseCoopers LLP
BIIB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BIIB
Upcoming Events for BIIB
Similar to BIIB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.